2014
Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).
Wesolowski R, Zhao M, Geyer S, Lustberg M, Mrozek E, Layman R, Macrae E, Zhang J, Hall N, Schregel K, Ottman S, Camp A, Chalmers J, Andreopoulou E, Villalona-Calero M, Shapiro C, Knopp M, Grever M, Ramaswamy B. Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC). Journal Of Clinical Oncology 2014, 32: 1074-1074. DOI: 10.1200/jco.2014.32.15_suppl.1074.Peer-Reviewed Original Research
2013
NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer.
Ramaswamy B, Zhang J, Hall N, Schregel K, Lustberg M, Wesolowski R, Mrozek E, Layman R, Olson E, Ottman S, Camp A, Chalmers J, Geyer S, Villalona-Calero M, Shapiro C, Grever M, Knopp M. NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 1023-1023. DOI: 10.1200/jco.2013.31.15_suppl.1023.Peer-Reviewed Original ResearchPET/CTFLT PET/CTAdvanced breast cancerPhase I trialFLT uptakeDay 7I trialBreast cancerPARP inhibitorsFDG PET/CTFLT PET uptakeFLT-PET imagingPARP inhibitor veliparibUptake of FLTCycle 3Dose-escalation designEligible ptsDose scheduleEscalation designFLT-PETFDG uptakeTrial protocolTherapy responseBlinded fashionImaging marker20P NCI 8609: Multicenter Phase I Trial of PARP Inhibitor Veliparib with Carboplatin in Advanced Breast Cancer
Ramaswamy B, Geyer S, Lustberg M, Wesolowski R, Andreopoulou E, Knopp M, Villalona M, Chen A, Grever M, Shapiro C. 20P NCI 8609: Multicenter Phase I Trial of PARP Inhibitor Veliparib with Carboplatin in Advanced Breast Cancer. Annals Of Oncology 2013, 24: iii19. DOI: 10.1093/annonc/mdt081.1.Peer-Reviewed Original Research